[Diagnostic-therapeutic trial in infantile genetic agranulocytosis with leucorecruitin].

Subject of this report is the usefulness of a biologically specific mediator of the leucocytosis reaction (leucorecruitin) in the diagnostic evaluation of granulopenic diseases. According to our trial the application of leucorecruitin in healthy humans resulted in a significant increase of granulocytes in circulating blood. The therapeutic effect depends on the neutrophil storage pool. In a diagnostic-therapeutic trial in infantile genetic agranulocytosis with depleted storage pools, leucorecruitin failed to lift the low number of circulating granulocytes to a normal level. No side effects could be observed so far.